
Opinion|Videos|November 16, 2026
Rethinking Testosterone Therapy After the FDA Label Revisions
Fact checked by: Hannah Clarke
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.
Advertisement
Advertisement
Decades of fear about testosterone therapy rested on weak evidence, and the regulatory record is finally catching up with the science. Moderated by Dr. Amy Pearlman, this webinar brings together Dr. Abraham Morgentaler, Dr. Mohit Khera, and Dr. Helen Bernie, 3 members of the December 2025 FDA expert panel on testosterone therapy for men.
Related to this article

Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
Advertisement
Advertisement



